Salbutamol

Short-acting selective beta-2 adrenoreceptor agonists (SABA)

ATC code: R03AC02 (Salbutamol)

Brand names

Ventolin, ProAir, Proventil

Mechanism of action

Selectively stimulates beta-2 adrenoreceptors in bronchial smooth muscle. Activates adenylate cyclase, raises intracellular cAMP, and causes smooth muscle relaxation and bronchodilation. Onset 5-15 minutes after inhalation, peak 30-90 minutes, duration 4-6 hours. At high doses selectivity decreases, producing systemic beta-1 effects – tachycardia and tremor.

Indications

Acute bronchospasm

First line

Salbutamol is first-line for bronchospasm attack in asthma, COPD, and exercise- or allergen-induced bronchospasm. GINA 2024, GOLD 2024, NICE NG80 and NG115 recommend salbutamol or an equivalent SABA (terbutaline, fenoterol) as the primary rescue bronchodilator. Dose via pMDI with spacer: 4-10 puffs of 100 mcg during a severe attack, repeated every 20 minutes during the first hour if needed.

Used in children from the first year of life on clinical grounds. Always via spacer, with a face mask for the youngest.

Asthma

First line

GINA 2024 changed the SABA approach substantially. In adults and adolescents aged 12+, 'salbutamol-only-as-needed' monotherapy is no longer recommended, even in mild asthma. First-line is low-dose inhaled corticosteroid plus formoterol as needed (MART) or low-dose ICS plus SABA as needed. Salbutamol remains a rescue bronchodilator during attacks and a pre-exercise bronchodilator.

Use of more than 1 SABA inhaler per month (200 doses) is a marker of poorly controlled asthma and increased risk of severe exacerbation.

Chronic obstructive pulmonary disease

First line

GOLD 2024 recommends salbutamol as a rescue bronchodilator in COPD. Maintenance therapy relies on long-acting bronchodilators (LAMA and/or LABA), while SABA is used on demand for episodes of dyspnea.

Exercise-induced bronchoconstriction

First line

Salbutamol 200 mcg via pMDI 10-15 minutes before exercise effectively prevents exercise-induced bronchoconstriction in asthma and in individuals without chronic asthma who have airway reactivity.

Muscle mass gain (bodybuilding self-use)

Not recommended

In bodybuilding salbutamol is used on rumours of anabolic beta-2 agonist effects. Controlled human studies do not demonstrate clinically meaningful muscle mass gain. Attributed effects are limited to weight loss and metabolic rate increase – not muscle growth. WADA lists beta-2 agonists as prohibited in most contexts. High-dose use carries substantial arrhythmia and sudden-death risk.

Weight loss in non-diabetics (marketed indication)

Not recommended

In fitness communities salbutamol is sometimes used as a 'clenbuterol replacement' for thermogenic effects and weight loss. This use is dangerous: tachycardia, tremor, hypokalaemia, and arrhythmias at systemic doses, especially combined with other beta-agonists. International obesity guidelines (NICE, WHO) do not mention salbutamol. Inhaled delivery has minimal systemic bioavailability, so 'weight loss' use requires oral administration or high doses – doubling the risk.

Practical notes

technique

Correct pMDI technique is the key to efficacy. A spacer is always recommended: it increases pulmonary deposition by 30-50% and reduces local adverse effects. In children and older patients, technique without a spacer is often inadequate. Nebuliser is used in hospital and for severe attacks in outpatients with poor inhaler technique.

overuse_warning

SABA overuse is a serious warning sign. Patients who use SABA daily or more are at risk of severe exacerbation and asthma death. SMART trials and SABINA global showed a direct link between high SABA use and hospitalisation risk. In this scenario, baseline therapy must be reviewed and ICS added, not simply a new inhaler prescribed.

Safety

Contraindications

Hypersensitivity to salbutamol or excipients
Use with caution in severe coronary disease, uncontrolled hypertension, tachyarrhythmias, severe thyrotoxicosis

Serious adverse effects

Paradoxical bronchospasm (rare, requires immediate discontinuation)
Hypokalaemia at high doses, especially combined with diuretics, theophylline, or corticosteroids
Severe arrhythmias on overdose

Common adverse effects

Tremor
Tachycardia, palpitations
Headache
Oropharyngeal irritation

Pregnancy

Extensive pregnancy data are available. No fetal risk has been confirmed. Poorly controlled asthma in pregnancy is more dangerous than salbutamol use. It is continued as indicated throughout pregnancy.

Breastfeeding

Compatible with breastfeeding. Systemic absorption after inhalation is minimal.

Frequently asked

What is Salbutamol used for?

Salbutamol is evaluated for the following indications with varying evidence strength: Acute bronchospasm (evidence tier A), Chronic obstructive pulmonary disease (evidence tier A), Exercise-induced bronchoconstriction (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Salbutamol?

Common side effects of Salbutamol (≥ 1 in 100): Tremor, Tachycardia, palpitations, Headache, Oropharyngeal irritation. See the Safety section for uncommon and serious reactions.

Is Salbutamol safe during pregnancy?

Is Salbutamol compatible with breastfeeding?

Compatible with breastfeeding. Systemic absorption after inhalation is minimal.

Who should not take Salbutamol?

Salbutamol is contraindicated in: Hypersensitivity to salbutamol or excipients; Use with caution in severe coronary disease, uncontrolled hypertension, tachyarrhythmias, severe thyrotoxicosis. Full list in the Safety section.